Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ANP009
MIFTS: 44

Anaplastic Oligodendroglioma

Categories: Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Anaplastic Oligodendroglioma

About this section

MalaCards integrated aliases for Anaplastic Oligodendroglioma:

Name: Anaplastic Oligodendroglioma 53 59 55 73

Characteristics:

Orphanet epidemiological data:

59
anaplastic oligodendroglioma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

Orphanet 59 ORPHA251630
ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 74 C0334590
UMLS 73 C0334590
Sources

Summaries for Anaplastic Oligodendroglioma

About this section
MalaCards based summary : Anaplastic Oligodendroglioma is related to oligoastrocytoma and oligodendroglioma, and has symptoms including seizures and headache. An important gene associated with Anaplastic Oligodendroglioma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial), and among its related pathways/superpathways are Glioma and DNA Damage. The drugs Carmustine and Dacarbazine have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and t cells, and related phenotypes are Decreased viability and Decreased viability

Sources

Related Diseases for Anaplastic Oligodendroglioma

About this section

Diseases related to Anaplastic Oligodendroglioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Related Disease Score Top Affiliating Genes
1 oligoastrocytoma 30.6 GFAP IDH2 MGMT
2 oligodendroglioma 30.1 CDKN2A CDKN2C EGFR GFAP IDH2 MGMT
3 brain cancer 29.6 EGFR GFAP IDH2 MGMT
4 glioblastoma 29.6 CDKN2A EGFR IDH2 MGMT
5 lynch syndrome 29.6 CDKN2A EGFR MGMT
6 grade iii astrocytoma 29.1 CDKN2A EGFR GFAP IDH2 MGMT
7 arteriovenous malformation 10.2
8 astrocytoma 10.2
9 gemistocytic astrocytoma 10.1 GFAP IDH2
10 protoplasmic astrocytoma 10.1 GFAP IDH2
11 leukemia 10.1
12 glioma susceptibility 1 10.1 GFAP IDH2
13 pleomorphic xanthoastrocytoma 10.1 GFAP MGMT
14 spinal cord astrocytoma 10.1 GFAP MGMT
15 periosteal chondrosarcoma 10.1 CDKN2A IDH2
16 breast giant fibroadenoma 10.0 CDKN2A MGMT
17 cornea cancer 10.0 CDKN2A GFAP
18 atypical neurofibroma 10.0 CDKN2A GFAP
19 necrotizing sialometaplasia 10.0 CDKN2A GFAP
20 central nervous system lymphoma 10.0 CDKN2A MGMT
21 juvenile pilocytic astrocytoma 10.0 CDKN2A GFAP
22 cerebral cavernous malformations 10.0
23 multiple sclerosis 10.0
24 williams-beuren syndrome 10.0
25 psoriatic arthritis 10.0
26 leukemia, acute lymphoblastic 10.0
27 acute leukemia 10.0
28 acute lymphoblastic leukemia, childhood 10.0
29 arthritis 10.0
30 hydrocephalus 10.0
31 lymphoma 10.0
32 lymphocytic leukemia 10.0
33 pancytopenia 10.0
34 central neurocytoma 10.0
35 gangliocytoma 10.0
36 agammaglobulinemia 10.0
37 adenocarcinoma 10.0
38 mixed glioma 10.0
39 ganglioglioma 10.0
40 cerebral lymphoma 10.0
41 paraplegia 10.0
42 cerebellar liponeurocytoma 10.0
43 anaplastic oligoastrocytoma 10.0
44 thunderclap headache 10.0
45 headache 10.0
46 brain stem glioma 10.0 EGFR IDH2
47 fibrillary astrocytoma 10.0 GFAP IDH2 MGMT
48 gliomatosis cerebri 9.9 EGFR GFAP
49 malignant peritoneal mesothelioma 9.9 CDKN2A EGFR
50 peritoneal mesothelioma 9.9 CDKN2A EGFR

Graphical network of the top 20 diseases related to Anaplastic Oligodendroglioma:



Diseases related to Anaplastic Oligodendroglioma
Sources

Symptoms & Phenotypes for Anaplastic Oligodendroglioma

About this section

UMLS symptoms related to Anaplastic Oligodendroglioma:


seizures, headache

GenomeRNAi Phenotypes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.77 EGFR
2 Decreased viability GR00221-A-1 9.77 CDKN2A EGFR POT1 CDKN2C
3 Decreased viability GR00221-A-3 9.77 CDKN2A POT1
4 Decreased viability GR00221-A-4 9.77 CDKN2A EGFR POT1
5 Decreased viability GR00301-A 9.77 CDKN2C
6 Decreased viability GR00342-S-2 9.77 CDKN2C
7 Decreased viability GR00402-S-2 9.77 CDKN2A EGFR POT1 CDKN2C

MGI Mouse Phenotypes related to Anaplastic Oligodendroglioma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.65 CDKN2A CDKN2C EGFR GFAP IDH2
2 neoplasm MP:0002006 9.55 CDKN2A CDKN2C EGFR IDH2 MGMT
3 no phenotypic analysis MP:0003012 9.26 CDKN2A EGFR MGMT POT1
4 respiratory system MP:0005388 8.92 CDKN2A CDKN2C EGFR MGMT
Sources

Drugs & Therapeutics for Anaplastic Oligodendroglioma

About this section

Drugs for Anaplastic Oligodendroglioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 323)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
2
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
3
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
4
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 57-22-7, 2068-78-2 5978
5
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
6
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1 13010-47-4 3950
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
9
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
10
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
13
Isotretinoin Approved Phase 3,Phase 1 4759-48-2 5538 5282379
14
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538 444795
15 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
16 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
18 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
19 Antimitotic Agents Phase 3,Phase 1,Phase 2
20 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
21 Dermatologic Agents Phase 3,Phase 1,Phase 2,Not Applicable
22 Keratolytic Agents Phase 3,Phase 1,Phase 2
23 Cola Phase 3,Phase 1
24 Adjuvants, Anesthesia Phase 3
25 Liver Extracts Phase 3,Phase 2,Phase 1
26 Anesthetics, Intravenous Phase 3
27 Analgesics, Opioid Phase 3
28 Peripheral Nervous System Agents Phase 3,Phase 1,Phase 2
29 Anesthetics, General Phase 3
30 Analgesics Phase 3,Phase 1,Phase 2
31 Narcotics Phase 3
32 Anesthetics Phase 3,Phase 1
33 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
34 Nootropic Agents Phase 3,Phase 2
35 Cholinergic Agents Phase 3,Phase 2
36 Cholinesterase Inhibitors Phase 3,Phase 2
37 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 Central Nervous System Stimulants Phase 3,Phase 2
39 Dopamine Agents Phase 3,Early Phase 1,Not Applicable
40 Serotonin Agents Phase 3
41 Anti-Allergic Agents Phase 3
42 Serotonin Antagonists Phase 3
43 Histamine H1 Antagonists Phase 3
44
Histamine Phosphate Phase 3 51-74-1 65513
45 Antipruritics Phase 3
46 Histamine Antagonists Phase 3
47 Dexmethylphenidate Hydrochloride Phase 3
48 Neurotransmitter Uptake Inhibitors Phase 3
49 Dopamine Uptake Inhibitors Phase 3
50
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202

Interventional clinical trials:

(show top 50) (show all 233)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00002569 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
3 Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma Completed NCT00002840 Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
6 Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
7 Phase III Trial of Anaplastic Glioma Without 1p/19q LOH Active, not recruiting NCT00626990 Phase 3 temozolomide
8 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
9 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
10 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3 Isotretinoin;Procarbazine Hydrochloride
11 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
12 Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas Unknown status NCT02238496 Phase 2 Perifosine;Temsirolimus
13 Temozolomide in Treating Patients With Recurrent or Progressive Malignant Glioma Unknown status NCT00004204 Phase 2 temozolomide
14 Bevacizumab in Recurrent Grade II and III Glioma Unknown status NCT01164189 Phase 2 Temozolomide
15 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
16 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2 Temozolomide
17 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2 Temozolomide
18 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Completed NCT00400816 Phase 2 temozolomide
19 Temozolomide in Treating Patients With Anaplastic Oligodendroglioma Completed NCT00003465 Phase 2 temozolomide
20 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Completed NCT00033280 Phase 2 temozolomide
21 Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma Completed NCT00003101 Phase 2 busulfan;lomustine;procarbazine hydrochloride;thiotepa;vincristine sulfate
22 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2 topotecan hydrochloride
23 Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Completed NCT01663012 Phase 2 Etirinotecan pegol
24 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2 MLN-518 (Tandutinib)
25 A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis Completed NCT00565721 Phase 2 Fluciclatide Injection - (AH111585 (F18))
26 Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms Completed NCT00004688 Phase 2 carmustine;mercaptopurine;streptozocin
27 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2 Bevacizumab
28 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas Completed NCT00047879 Phase 2 Thalidomide
29 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2 BIBF 1120
30 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2 ZD6474 (Vandetanib);Carboplatin
31 VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide Completed NCT00369590 Phase 2
32 FR901228 in Treating Patients With Recurrent High-Grade Gliomas Completed NCT00085540 Phase 1, Phase 2 depsipeptide
33 Fenretinide in Treating Patients With Recurrent Malignant Glioma Completed NCT00006080 Phase 2 fenretinide
34 Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00823797 Phase 2 Bendamustine Hydrochloride
35 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
36 Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Completed NCT01648348 Phase 1, Phase 2
37 Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma Completed NCT00112736 Phase 1, Phase 2 erlotinib;temsirolimus
38 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
39 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
40 Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas Completed NCT00042991 Phase 1, Phase 2 gefitinib
41 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2 cilengitide
42 Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma Completed NCT00087061 Phase 1, Phase 2 gimatecan
43 Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma Completed NCT00404248 Phase 1, Phase 2 terameprocol
44 Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas Completed NCT00268359 Phase 2 irinotecan hydrochloride
45 Temozolomide in Treating Patients With Recurrent High-Grade Glioma Completed NCT00619112 Phase 2 temozolomide
46 Efaproxiral Plus Carmustine in Treating Patients With Progressive or Recurrent Malignant Glioma Completed NCT00005855 Phase 1, Phase 2 carmustine;efaproxiral
47 Radiation Therapy in Treating Patients With Progressive or Recurrent Malignant Brain Tumors Completed NCT00003574 Phase 2
48 Procarbazine in Treating Patients With Recurrent Brain Tumor Completed NCT00004004 Phase 1, Phase 2 procarbazine hydrochloride
49 Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors Completed NCT00012038 Phase 1, Phase 2 irofulven
50 EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Completed NCT00006093 Phase 1, Phase 2 cilengitide

Search NIH Clinical Center for Anaplastic Oligodendroglioma

Sources

Genetic Tests for Anaplastic Oligodendroglioma

About this section
Sources

Anatomical Context for Anaplastic Oligodendroglioma

About this section

MalaCards organs/tissues related to Anaplastic Oligodendroglioma:

41
Brain, Bone, T Cells, Spinal Cord, Breast, Bone Marrow, Cerebellum
Sources

Publications for Anaplastic Oligodendroglioma

About this section

Articles related to Anaplastic Oligodendroglioma:

(show top 50) (show all 126)
# Title Authors Year
1
Tumour-to-Tumour Metastasis Phenomenon: Metastatic Prostatic Adenocarcinoma within an Anaplastic Oligodendroglioma in the Brain of a Dog. ( 30502799 )
2018
2
Machine Learning for Better Prognostic Stratification and Driver Gene Identification Using Somatic Copy Number Variations in Anaplastic Oligodendroglioma. ( 30018130 )
2018
3
Anaplastic oligodendroglioma with leptomeningeal dissemination in a french bulldog. ( 30185721 )
2018
4
Multiple Extraneural Metastases of Anaplastic Oligodendroglioma. ( 30283558 )
2018
5
Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted. ( 30289152 )
2018
6
Anaplastic oligodendroglioma metastasizing to the bone marrow: A unique case report and literature review. ( 30526175 )
2018
7
A Case of Anaplastic Oligodendroglioma With Extensive Extraneural Metastases Imaged With FDG PET. ( 29076897 )
2017
8
Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature. ( 28696020 )
2017
9
Genetic landscape of extreme responders with anaplastic oligodendroglioma. ( 28388591 )
2017
10
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. ( 28472509 )
2017
11
Multimodal 18F-Fluciclovine PET/MRI and Ultrasound-Guided Neurosurgery of an Anaplastic Oligodendroglioma. ( 28844925 )
2017
12
Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. ( 27401158 )
2016
13
Low-grade and anaplastic oligodendroglioma. ( 26948366 )
2016
14
Tumor cell-specific chromosomal abnormality in the vascular endothelial cells of anaplastic oligodendroglioma. ( 26771849 )
2016
15
Racial disparities in anaplastic oligodendroglioma: An analysis on 1643 patients. ( 28024733 )
2016
16
The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. ( 27651340 )
2016
17
A rare presentation of anaplastic oligodendroglioma metastatic to bone marrow, mimicking blast cells. ( 27302043 )
2016
18
Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. ( 26722084 )
2016
19
Spinal Anaplastic Oligodendroglioma With Oligodendrogliomatosis: Molecular Markers and Management: Case Report. ( 26352098 )
2016
20
Arteriovenous malformation within an isocitrate dehydrogenase 1 mutated anaplastic oligodendroglioma. ( 26167373 )
2015
21
Somatostatin Receptors in an Anaplastic Oligodendroglioma Relapse Evidenced By 68Ga DOTANOC PET/CT. ( 26018682 )
2015
22
Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. ( 25534576 )
2015
23
TCF12 is mutated in anaplastic oligodendroglioma. ( 26068201 )
2015
24
A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13-12. ( 26341368 )
2015
25
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. ( 26354927 )
2015
26
A case of mushroom-shaped anaplastic oligodendroglioma resembling meningioma and arteriovenous malformation: Inadequacies of diagnostic imaging. ( 26622514 )
2015
27
Increased 99mTc TRODAT-1 Uptake in Anaplastic Oligodendroglioma. ( 23603602 )
2014
28
Occipital anaplastic oligodendroglioma with multiple organ metastases after a short clinical course: a case report and literature review. ( 24447608 )
2014
29
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
30
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). ( 24812135 )
2014
31
Novel MSH6 mutations in treatment-naA^ve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. ( 25078279 )
2014
32
Cavernous angioma within the context of anaplastic oligodendroglioma: case report and review of the literature. ( 24844794 )
2014
33
Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. ( 25391968 )
2014
34
Anaplastic oligodendroglioma arising from the brain stem and featuring 1p/19q co-deletion. ( 23711170 )
2014
35
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. ( 24162809 )
2014
36
A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. ( 23527265 )
2013
37
Differential diagnosis of small cell glioblastoma and anaplastic oligodendroglioma: a case report of an elderly man. ( 23979650 )
2013
38
Anaplastic oligodendroglioma in an adolescent with Lynch syndrome. ( 23255519 )
2013
39
Leukemia-like onset of bone marrow metastasis from anaplastic oligodendroglioma after 17A years of dormancy: an autopsy case report. ( 23900511 )
2013
40
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. ( 23071247 )
2013
41
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. ( 23896377 )
2013
42
Temozolomide salvage chemotherapy for recurrent anaplastic oligodendroglioma and oligo-astrocytoma. ( 24527191 )
2013
43
Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. ( 23907441 )
2013
44
Feline anaplastic oligodendroglioma: long-term remission through radiation therapy and chemotherapy. ( 23651604 )
2013
45
Pitfalls of conservative treatments of multiple probable cerebral cavernous malformations (CCMs): clinicopathological features of CCMs coexisting with vasculogenic mimicry in an anaplastic oligodendroglioma. ( 24337536 )
2013
46
Extraneural metastases of anaplastic oligodendroglioma. ( 24373094 )
2013
47
Minding the Ps and Qs: perseverance and quality studies lead to major advances in patients with anaplastic oligodendroglioma. ( 23071223 )
2013
48
Emerging biomarkers in anaplastic oligodendroglioma: implications for clinical investigation and patient management. ( 25054579 )
2013
49
Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. ( 23071237 )
2013
50
Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience. ( 23681562 )
2013
Sources

Variations for Anaplastic Oligodendroglioma

About this section
Sources

Expression for Anaplastic Oligodendroglioma

About this section
Search GEO for disease gene expression data for Anaplastic Oligodendroglioma.
Sources

Pathways for Anaplastic Oligodendroglioma

About this section

Pathways related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Glioma 37
Show member pathways
 12.28 CDKN2A CDKN2C EGFR
2
DNA Damage 4
11.9 CDKN2A CDKN2C MGMT
3
Cushing syndrome 37
Show member pathways
 11.74 CDKN2A CDKN2C EGFR
4
Bladder cancer 37 1
11.27 CDKN2A EGFR
5
Regulation of Telomerase 1
11.19 EGFR POT1
6
Photodynamic therapy-induced AP-1 survival signaling. 1
11.03 CDKN2A EGFR
7
Glioblastoma Multiforme 64
10.84 CDKN2A EGFR MGMT
8
Oncogene Induced Senescence 66
10.46 CDKN2A CDKN2C
Sources

GO Terms for Anaplastic Oligodendroglioma

About this section

Biological processes related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of DNA repair GO:0045739 9.26 EGFR MGMT
2 negative regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045736 9.16 CDKN2A CDKN2C
3 negative regulation of phosphorylation GO:0042326 8.96 CDKN2A CDKN2C
4 obsolete negative regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031658 8.62 CDKN2A CDKN2C

Molecular functions related to Anaplastic Oligodendroglioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.13 CDKN2A CDKN2C EGFR
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CDKN2A CDKN2C
Sources

Sources for Anaplastic Oligodendroglioma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....